Stocklytics Platform
Asset logo for symbol VVOS
Vivos Therapeutics
VVOS70
$4.55arrow_drop_down0.86%-$0.04
High Growth
Penny Stock
Asset logo for symbol VVOS
VVOS70

$4.55

arrow_drop_down0.86%

Performance History

Chart placeholder
Key Stats
Open$4.66
Prev. Close$4.61
EPS-4.99
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$22.43M
PE Ratio-
LOWHIGH
Day Range4.41
4.77
52 Week Range0.24
48.79
Ratios
EPS-4.99

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Vivos Therapeutics (VVOS)

Vivos Therapeutics, Inc. (VVOS) is a company that specializes in providing innovative treatment solutions for individuals suffering from sleep apnea and other sleep-related disorders. The company's primary focus is on its proprietary Vivos System, which is a non-surgical, non-invasive, and patented treatment approach. The Vivos System aims to address the root cause of sleep apnea by expanding and remodeling the patient's airway, thereby improving breathing and reducing or eliminating the symptoms of sleep apnea. The Vivos System consists of custom-made oral appliances that are worn during sleep and gently guide the patient's jaw into a forward position, preventing the collapse of the airway. This innovative approach has been proven to be effective in clinical studies and has gained recognition from the medical community.
Vivos Therapeutics, Inc. has experienced significant growth and success in recent years. The company's stock price history shows a steady upward trend, reflecting investor confidence in the company's products and potential. With a market cap of [MARKET_CAP], Vivos Therapeutics is well-positioned to continue its growth trajectory and expand its market presence. The company's PEG ratio indicates that its stock price is relatively undervalued compared to its earnings growth, making it an attractive investment opportunity for value-seeking investors. Vivos Therapeutics has also outperformed the industry, as indicated by its strong performance compared to industry benchmarks. This suggests that the company has a competitive advantage and is well-positioned to capture a larger market share.
Sector
Healthcare
Industry
Medical Devices
CEO
Mr. R. Kirk Huntsman
Headquarters
Littleton
Employees
154
Exchange
NASDAQ
add Vivos Therapeutics to watchlist

Keep an eye on Vivos Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Vivos Therapeutics's (VVOS) price per share?

The current price per share for Vivos Therapeutics (VVOS) is $4.55. The stock has seen a price change of -$0.04 recently, indicating a -0.87% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Vivos Therapeutics (VVOS)?

For Vivos Therapeutics (VVOS), the 52-week high is $48.79, which is 972.31% from the current price. The 52-week low is $0.24, the current price is 1.78K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Vivos Therapeutics (VVOS) a growth stock?

Vivos Therapeutics (VVOS) has shown an average price growth of -2.59% over the past three years. It has received a score of 99 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Vivos Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Vivos Therapeutics (VVOS) stock price performance year to date (YTD)?

As of the latest data, Vivos Therapeutics (VVOS) has a year-to-date price change of -61.44%. Over the past month, the stock has experienced a price change of 41.74%. Over the last three months, the change has been 53.72%. Over the past six months, the figure is 84.21%.
help

Is Vivos Therapeutics (VVOS) a profitable company?

Vivos Therapeutics (VVOS) has a net income of -$13.58M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 55.43% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -47.76% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $13.8M, although specific revenue growth data is currently not available. The gross profit is $7.65M. Operating income is noted at -$17.3M. Furthermore, the EBITDA is -$12.9M.
help

What is the market capitalization of Vivos Therapeutics (VVOS)?

Vivos Therapeutics (VVOS) has a market capitalization of $22.44M. The average daily trading volume is 4.62, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level